Vida Diagnostics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to add automated segmentation to its artificial intelligence (AI)-powered lung analysis software, LungPrint.
The clearance allows Vida to add deep-learning algorithms for lung and lobe segmentation to LungPrint. The new algorithms enable the software to perform improved lung imaging analysis and provide more comprehensive assessments of disease likelihood and progression, Vida noted.
Clinicians can use the new segmented data to develop personalized treatment plans. The clearance also further validates the clinical qualification of the software, according to the company.
